We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01155739
Recruitment Status : Completed
First Posted : July 2, 2010
Last Update Posted : December 19, 2014
Information provided by (Responsible Party):
Nicolas DEMARTINES, University of Lausanne Hospitals

Brief Summary:
Procalcitonin level used for determining length of antibiotic treatment in peritonitis and intra-abdominal infections. Hypothesis is that length of antibiotic use can be shortened by this method.

Condition or disease
Secondary or Tertiary Peritonitis

Detailed Description:
Prospective randomized trial

Study Type : Observational
Actual Enrollment : 162 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Etude Prospective Sur l'Impact de l'Utilisation de la Procalcitonine Dans l'évaluation de la Poursuite ou de l'arrêt du Traitement Antibiotique Empirique Lors de péritonites et d'Infections Intra-abdominales
Study Start Date : June 2009
Primary Completion Date : June 2014
Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics
U.S. FDA Resources

procalcitonine monitoring
PCT group: antibiotic use is tailored by serum procalcitonin values, determined every 48houres.
control group
control group: antibiotic use and length of treatment as defined by guidelines

Primary Outcome Measures :
  1. antibiotic treatment length, hospitalisation length without antibiotic, infection recurrence, antibiotic cost [ Time Frame: at one month and during hospital stay ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
hospitalized patients with SIRS due to peritonitis or intra-abdominal infections

Inclusion Criteria:

  • More than 18 yo
  • Patient requiring surgery for peritonitis or intra-abdominal infection following: perforation, necrosis, previous operation...
  • Mannheim Peritonitis score > 14
  • SIRS present
  • Probability of survival > 72h
  • Informed consent by patient/relatives

Exclusion Criteria:

  • No SIRS
  • Long date corticoid treatment
  • Immunosuppression
  • Thyroid medullary carcinoma
  • Anaphylactic shock
  • Acute hepatic deficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01155739

University Hospital of Lausanne
Lausanne, Switzerland, 1011
Sponsors and Collaborators
University of Lausanne Hospitals
Principal Investigator: Steve Aellen, MD Department of visceral surgery, university hospital

Responsible Party: Nicolas DEMARTINES, professor of surgery, University of Lausanne Hospitals
ClinicalTrials.gov Identifier: NCT01155739     History of Changes
Other Study ID Numbers: 141/08, Propéritonite
First Posted: July 2, 2010    Key Record Dates
Last Update Posted: December 19, 2014
Last Verified: December 2014

Additional relevant MeSH terms:
Intraabdominal Infections
Peritoneal Diseases
Digestive System Diseases
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents
Bone Density Conservation Agents
Physiological Effects of Drugs